November 1, 2017
SNMMI was well represented on the Commission.
The Lancet Oncology Commission has issued a major report, published in The Lancet Oncology journal, that sets out how to accelerate cancer research and care in order to reach the goals of the U.S. Cancer Moonshot initiative. It calls for a fundamental shift in how cancer research is conducted and how cancer care is delivered in the United States.
A number of SNMMI members served as commissioners and contributed to development of this report. They include
The report sets out a detailed roadmap to deliver on the Blue Ribbon Panel recommendations, including a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups. The report also emphasizes the importance of addressing health disparities in all recommendations.
The Lancet Oncology Commission on Future Research Priorities in the USA is authored by over 50 leading oncologists, including members of leading U.S. cancer organizations, and sets out 13 key priority areas, each with measurable goals, to focus the $2 billion in funding released to the National Cancer Institute as part of the 21st Century Cures Act.
It highlights how technological advances, including understanding and mapping pre-cancer biology and the rapid adoption of big data, as well as new collaborations across industry, patient groups, academia, government and clinical practice will be critical to advancing research, and ultimately improving patient care.
The Commission report was launched on November 1 at an event on Capitol Hill. Now the work of carrying out the steps it outlines gets underway.
Commission Report on Future Research Priorities in the USA (interactive report)
Commission Report on Future Research Priorities in the USA (downloadable report, free with free registration)